"Recovery" after hand embolization means two different things: getting over the procedure itself, and waiting to see whether the arthritis pain eases. The published studies say a lot about the second and almost nothing about the first. This timeline sticks to what those studies measured and is plain about the gaps. For an overview of the treatment, see our hand arthritis embolization page.
Read this first: what the timeline is built on
Five small studies of embolization for hand osteoarthritis have been published, with 204 patients in total. All five are uncontrolled case series. Everyone was treated, and no group received a placebo procedure, a splint or an injection for comparison. There is no randomized trial for the hand.
So every figure below is a before-and-after number. It cannot be separated from the placebo response, from the natural ups and downs of hand arthritis, or from other treatments patients kept using. In the knee, where placebo-controlled trials exist, results have been mixed. Read the numbers as what was observed in specific small groups, not as a forecast for you.
The first hour
The only study with full procedural detail is a 2024 pilot from Taiwan with 9 patients. In that study, the treated hand turned pale in all 9 and returned to its normal color about 30 minutes after the infusion. The wrist puncture was pressed by hand and covered with a band-aid, and patients were discharged after 20 minutes of observation.
What the procedure itself involves is covered in is hand arthritis embolization painful.
The first week
Only the Taiwan pilot measured pain this early. At 1 week, average overall pain had fallen by 55% and average night pain by 62%. Six of the 9 patients had at least a 50% drop in pain.
That is 9 people in one hospital. It shows early relief is possible, not that it is typical. No study reports what the wrist or hand felt like in the days after the procedure.
One month: early relief, a possible setback, and a second session
The one-month mark is where the studies get more interesting.
- Taiwan pilot, 9 patients: 7 of 9 had at least a 50% drop in pain. But 4 of the 9 (44.4%) had what the authors called early recurrence, meaning pain had partly come back, though it was milder than before treatment.
- Liang 2023, Taiwan, 58 patients with finger joint arthritis: 62.1% rated themselves improved at 1 month, the lowest figure of the first six months in that study.
- Konduru 2026, North Carolina, 14 patients with thumb base arthritis: the average pain score (VAS) went from 8.0 to 3.1 at 1 month.
The Taiwan authors suggested the early return of pain may happen because the treated vessels partly reopen, and that two sessions may be the appropriate plan. Every patient in that study had a second session at 1 month. The largest study, Kubo 2023 from Japan with 92 patients, also planned two procedures, the second coming 1 to 2 months after the first.
The practical point: two of the five studies planned two sessions, and the others do not say how many sessions patients had. If you are evaluated for it, ask how many sessions are planned.
Questions about your treatment options? Dr. Fox can help.
Book a ConsultationThis article is part of our Embolization Guide.
Three to six months: where most of the data sit
Each study defined "response" differently, so the percentages below cannot be averaged or compared directly. They are shown study by study on purpose.
| Study (all uncontrolled case series) | How response was defined | Share responding, by time point |
|---|---|---|
| Lee 2024, 9 patients, mixed hand arthritis | At least a 50% drop in pain | 1 week: 6 of 9. 1 month: 7 of 9. 3 months: 8 of 9. 6 months: 8 of 9 |
| Liang 2023, 58 patients, finger joints | Patient's own rating of improvement | 1 month: 62.1%. 3 months: 77.6%. 6 months: 70.7%. 12 months: 63.4% (30 patients followed that long). 18 months: 50.0% (6 patients followed that long) |
| Kubo 2023, 92 patients, finger joints | Pain lower by at least 2 points out of 10 | 12 months: 77% |
| Inui 2021, 31 patients, thumb base | Patient's own rating of improvement | 2 months: 84%. 6 months: 81%. 24 months: 77% |
| Konduru 2026, 14 patients, thumb base | At least a 50% drop in pain | By 6 months: 11 of 14 (79%) |
In the Liang study, average pain was lowest at 3 months (2.2 out of 10, down from 6.0). In the Taiwan pilot, the share with returning pain fell to 1 in 9 at both 3 and 6 months, after the second session.
Pain medicine use was tracked in the pilot only. Regular use of oral anti-inflammatory medicine went from 55.6% of patients before treatment to 11.1% at 6 months. Patients in that study were allowed to continue other conservative treatments. The authors list that, and a possible placebo effect from having no control group, among the study's limitations.
Twelve to 24 months: fewer patients, some fading
Long-term information is thin, and it points in two directions.
- Some fading. In Liang 2023, average pain drifted from 2.2 at 3 months to 2.8 at 12 months and 2.9 at 18 months, and the share rating themselves improved fell from 77.6% at 3 months to 63.4% at 12 months and 50.0% at 18 months. Only 30 of the 58 patients were followed to 12 months and only 6 to 18 months, so the 18-month figure describes 6 people.
- Pain reduced, not gone. In Kubo 2023, average pain went from 7.8 out of 10 to 3.8 at 3 months and 4.0 at 12 months. About 1 in 4 patients did not reach the study's definition of success at 12 months.
- Some holding. In Inui 2021, 77% of 31 patients with thumb base arthritis still rated themselves improved at 24 months, with average pain at 2.5 out of 10 compared with 7.2 before. This is the longest follow-up published. Results are counted from the first procedure, and the summary does not say how many patients had more than one.
Nothing has been published beyond 24 months. No study reports how many patients needed repeat treatment after the planned sessions, or whether embolization changes the need for later hand surgery. A fuller look at the evidence is in what the hand embolization studies show.
Function and stiffness: a more modest picture
Pain is not the whole story for a hand. On this point the studies are less consistent.
Hand function questionnaires improved in three studies. In Kubo 2023, a disability score (QuickDASH, where lower is better) went from 27 to 19 at 12 months. In Liang 2023, a hand function score went from 9.8 to 4.1 at 3 months. In Inui 2021, the QuickDASH score went from 49.2 to 19.5 at 24 months.
The Taiwan pilot is the caution. Its function score improved at 1 week and 1 month, but the change was not statistically significant at 3 or 6 months. Stiffness did not change significantly at any time point. No published summary reports grip or pinch strength.
Embolization does not rebuild cartilage or change the shape of a joint. If stiffness or weakness limits you more than pain does, embolization has no evidence of helping. Hand exercise and splints are what guidelines conditionally recommend for hand osteoarthritis. See hand arthritis treatment without surgery.
What no study reports: time off work and activity limits
This needs to be said plainly. None of the published hand embolization studies reports:
- Time off work
- Activity restrictions after the procedure
- When patients drove, typed, lifted or gripped again
- Whether a splint was worn afterward
Any website that gives you a specific number of rest days for hand embolization is not getting it from the research. These instructions depend on the doctor, the technique and your work. Dr. Fox evaluates patients for hand and finger embolization at our Manhattan office, and your aftercare plan should come from him directly, in writing, before you schedule.
When to check in sooner
Because the studies give no aftercare schedule, follow the instructions you are given. As a general rule, call the office if pain is clearly worse than before the procedure, if the wrist puncture site bleeds or swells, or if a finger looks pale or blue or feels cold or numb after you have gone home. A finger that stays pale, blue or cold needs same-day medical attention. The reasoning behind these warning signs is in our article on risks and side effects.
For how recovery compares across other joints, visit our embolization guide.
Frequently Asked Questions
How soon does pain relief start after hand embolization?
In a 2024 pilot study of 9 patients, average overall pain was 55% lower at 1 week and 6 of 9 patients had at least a 50% drop. That is a very small uncontrolled study, and the larger studies first measured pain at 1 to 3 months.
How long do the results last?
The longest published follow-up is 24 months in 31 patients with thumb base arthritis, of whom 77% still rated themselves improved. In a 58-patient finger study, the share improved fell to 50.0% at 18 months, with only 6 patients followed that long.
Can the pain come back?
Yes. In the 9-patient pilot, pain had partly returned at 1 month in 4 patients, though milder than before, and every patient had a second session. In the largest study, about 1 in 4 patients did not meet the definition of success at 12 months.
How much time off work will I need?
No published hand embolization study reports time off work or activity restrictions. Ask the treating doctor for specific instructions based on your job and the technique used.
Will my hand stiffness improve?
It may not. In the one study that reported stiffness in detail, it did not change significantly at any time point, and function gains were not statistically significant at 3 and 6 months.
Keep Reading
- Hand and Finger Arthritis Embolization in Manhattan
- Hand Arthritis Embolization Research: What the Studies Show
- Hand Arthritis Embolization: Risks and Side Effects
- Hand Arthritis Embolization vs. Steroid Injections and Surgery
- Hand Arthritis Treatment Without Surgery: What the Guidelines Recommend
- Hand and Finger Osteoarthritis: Causes, Symptoms and Diagnosis
- Embolization Guide: knee, heel, shoulder, elbow and hip
Sources
- Lee et al., Diagn Interv Radiol, 2024: Short-term outcomes of transarterial embolization for hand osteoarthritis (9 patients, retrospective pilot)
- Lee et al., Diagn Interv Radiol, 2024: full text with technique, adverse events and limitations
- Liang et al., J Vasc Interv Radiol, 2023: Intra-arterial imipenem/cilastatin infusion for finger joint osteoarthritis pain (58 patients, retrospective single-arm)
- Kubo et al., Cardiovasc Intervent Radiol, 2023: Temporary embolic injection through a radial or ulnar artery needle for finger joint osteoarthritis (92 patients, retrospective)
- Inui et al., J Vasc Interv Radiol, 2021: Imipenem/cilastatin infusion through a radial artery needle for thumb base osteoarthritis (31 patients, prospective single-arm)
- Konduru et al., Hand (N Y), 2026: Prospective analysis of transarterial embolization for thumb base osteoarthritis (14 patients, single US clinic)
- Pelage et al., CVIR Endovasc, 2026: Indication-stratified review of musculoskeletal embolization (hand joints rated hypothesis-generating)
- Can et al., Radiologie, 2026: Review of transarterial embolization for joint pain (emerging data for hip and hand)
Medically reviewed by David Fox, MD, FACS, RPVI. This article is general information, not a substitute for a medical evaluation.
Living with joint or tendon pain that hasn’t improved? Schedule a consultation with Dr. David Fox at Fox Vein & Vascular in Manhattan to find out whether embolization is right for you. Call (212) 362-3470 or request an appointment online.

